KNI-174
KNI-174 is a potent and selective HIV-1 protease inhibitor and antiviral agent. KNI-174 targets and inhibits HIV-1-specific aspartic protease, thereby blocking retroviral proliferation. KNI-174 can be used in research related to acquired immunodeficiency syndrome (AIDS).
For research use only. We do not sell to patients.
- CAS No.: 141804-42-4
- Formula: C36H45N5O7S
- Molecular Weight:691.84
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
Biological Activity
Description
IC50 & Target
[1]|
HIV-1 |
Cellular Effect
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| ATH-8 cell line | IC50 |
276 ng/mL
|
HIV-1 antiviral activity against ATH8 cells, quantified as inhibition of HIV-1 replication.
HIV-1 antiviral activity against ATH8 cells, quantified as inhibition of HIV-1 replication.
|
8490108 |
In Vitro
KNI-174 potently inhibits HIV-1 replication in the ATH8 cell line with an IC50 of 276 ng/mL (0.40 μM)[1].
KNI-174 potently inhibits HIV-1 replication in PHA-PBM with an IC50 of 138 ng/mL (0.20 μM)[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
Parmacokinetics
| Species | Dose | Route | T1/2 (Elimination) | CLtotal | V1 | Vdss | MRT | AUC0-last | AUC0-∞ | T1/2 (Distribution) |
|---|---|---|---|---|---|---|---|---|---|---|
| Rat[1] | 10.0 mg/kg | i.v. | 3.97 h | 9.53 mL/min | 544 mL/kg | 7070 mL/kg | 3.14 h | 4.42 μg·h/mL | 4.80 μg·h/mL | 5.07 min |
Chemical Information
-
CAS No. 141804-42-4
-
Molecular Weight 691.84
-
Formula C36H45N5O7S
-
SMILES
CC(C)(C)NC([C@H]1N(CSC1(C)C)C([C@@H](O)[C@@H](NC([C@H](CC(N)=O)NC(COC2=CC=CC3=C2C=CC=C3)=O)=O)CC4=CC=CC=C4)=O)=O
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocols
-
Research Protocol for Infectious Diseases
Infectious-disease experiments test how pathogens interact with host barriers, innate immune receptors, inflammatory signaling, pathogen replication, and tissue injury; pattern-recognition receptors such as TLRs, RIG-I-like receptors, NOD-like receptors, and inflammasomes detect microbial molecules and activate NF-κB, interferon, and cytokine responses. The central hypothesis is that infection severity reflects the balance between pathogen burden and host response: protective inflammation restricts pathogen growth, whereas excessive or mislocalized inflammation contributes to tissue damage and disease phenotype. Unresolved questions include which host pathways are protective versus pathogenic, why some infection models fail to translate to human disease, and which combined readouts best predict clinically relevant infection outcomes.
-
Cell Viability Determination by MTT Colorimetric Assay
The following protocol uses the MTT colorimetric assay as a classic literature-established method for assessing cell viability/metabolic activity in cultured mammalian cells. MTT[3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide] is reduced by metabolically active cells to a colored formazan product; the amount of formazan is quantified spectrophotometrically and provides an indirect measure of metabolically active viable cells. Importantly, MTT reduction reflects cellular oxidoreductase/metabolic activity rather than an absolute direct count of living cells, so changes in cellular metabolism can alter the signal independently of cell number.
Purity & Documentation
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)